Biocept

Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-related DNA. Biocept's mission is to improve diagnostic outcomes for cancer patients by advancing oncology diagnostics. Using proprietary and innovative technologies, Biocept provides clinically relevant tumor diagnostics to guide patient treatment processes by offering advanced predictive and prognostic assessments for physicians. Additionally, Biocept offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept’s strategic focus is promoting its Selector Technology to the oncology community. Biocept’s Target Selector Technology has demonstrated the ability to consistently capture extremely rare cells that may be present at a frequency of only 1 cell per 50 to 100 billion blood cells. Examples of these rare cells are circulating tumor cells (CTCs) found in patients with early-stage, metastatic, or recurrent cancer. Biocept provides products and services to detect and analyze these rare cells to deliver information that physicians can use to make treatment decisions. Biocept employs unique laboratory tests by serving medical oncologists, surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Biocept has established partnerships with strategic industry leaders as well as major cancer centers.